Authors
Sr. Principal, Patient Analytics and AI, Global Commercial Solutions, IQVIA. With over 20 years of research experience, including 17 years at IQVIA, Göksu has extensive expertise in designing innovative approaches to analyze complex market dynamics using patient-level analytics. Her recent work focuses on building predictive models to facilitate earlier diagnosis and treatment of patients, as well as implementing AI-driven solutions for clinical decision support, web-based screening, and point-of-care tools. She has a strong therapeutic focus on autoimmune disorders, neuroscience, rare diseases, and cardiovascular and respiratory diseases.
Prior to joining IQVIA, Göksu worked at Eli Lilly, where she designed primary market research studies and conducted survey data analysis.
Sissi Pham, PharmD, is the CEO of AESARA Inc.
Principal, pharma launch strategy, at ZS. Since joining ZS in 2011, she has advised many clients on a range of topics including go-to-market strategy and launch differentiation in specialty pharma; commercial organizational design and integrated marketing (commercial, payer and patient); rare disease launch strategy and digitally enabled commercialization; prelaunch strategy and cross-functional unmet needs assessment (commercial, medical and market access); commercial operations optimization and portfolio cost efficiency; execution leadership on large immunology launches; and cross-functional coordination.
A recognized expert and thought leader across marketing advisory, launch planning, portfolio and brand planning, Gurnani regularly publishes on healthcare and pharma industry trends. She has supported 40+ clients across immunology, cardiology, respiratory, diabetes/metabolics, renal-hepatic and oncology.
Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry. She has extremely wide experience of international pharmaceutical industry issues, consulting to the world’s leading pharmaceutical companies on global issues. She has been Vice President, European Thought Leadership at IQVIA for 13 years. Sarah presents to hundreds of pharmaceutical industry clients every year on a range of global pharmaceutical industry issues and publishes white papers on many topics including the uptake and impact of innovative medicines and challenges for Launch Excellence. Sarah holds a degree in biochemistry from Oxford University.
Director, Product Offering and Strategy, at IQVIA
Senior director, biopharmaceutical CMC and regulatory affairs, Cencora
Pharmaceutical & Life Sciences Lead, PwC
Co-founder and CEO, ixlayer
Jane Li is the Senior Director of Pharma CDx and CRO Partnerships at Thermo Fisher Scientific, where she leads global strategy to expand the use of next-generation sequencing (NGS) in precision oncology. With over 25 years of experience in life sciences and diagnostics, she blends scientific expertise with business leadership to drive innovation.
Jane has helped launch and scale NGS-based oncology testing services, built key partnerships with pharma and cancer centers across the U.S. and Asia, and led cross-functional teams in both large organizations and fast-paced startup environments. Her work focuses on turning complex science into real-world solutions that improve patient outcomes.
Associate product and strategy director, global commercial offerings, IQVIA.
Partner, Dubai, with Simon-Kucher & Partners life sciences division
AI in Drug Discovery On-Demand Webinar
Janice MacLennan is CEO of Nmblr, the Biopharma and MedTech collaborative strategy platform. With over 30 years’ experience helping Biopharma and Medical Device companies tackle complex commercial challenges and develop winning strategies, she brings deep industry insight and personal passion to her work. Janice has dedicated her career to supporting the delivery of breakthrough therapies through consultancy partnerships with big and mid-sized companies across the globe. At Nmblr, she leads efforts to humanize strategy - empowering teams to align, adapt, and move as one to make better decisions and ensure innovations are delivered successfully, and to a receptive market.
Director, Boston, with Simon-Kucher & Partners’ life sciences division
Head of Pharmacy, RazorMetrics
Senior Associate, Shabas Solutions LLC.
Chief strategy officer with Marken UPS Healthcare Precision Logistics. Bell joined legacy Marken in 2003. He is a licensed US Customs Broker and a certified customs specialist with more than 26 years of experience in the life science logistics and temperature control field.
Bell is responsible for leading the strategy, marketing, and pricing teams at Marken, UPS Healthcare Precision Logistics, with a focus on finding new ways to innovate, optimize, and solve clients’ greatest challenges. He has served as a liaison between clients, customs, and the alphabet soup of regulatory agencies to ensure the maximum level of compliance with trade laws and regulations.
As regulatory scrutiny continues to focus on the temperature-controlled supply chain, Bell’s expertise with thermoregulating packaging solutions and temperature logging devices has been critical to meeting the requirements of the recently updated Good Distribution Practices for pharmaceutical transport and similar guidelines.
A product and strategy leader with 17 years of experience in market research, consulting and product development. As director, Agentic AI, he leads development and commercial strategy of Agentic AI solutions layered across IQVIA’s gold standard syndicated data assets. With over 11 years at IQVIA, he drives incremental value to customers through business strategy, product development, and AI-powered solutions and data-driven insights. His responsibilities include leading product development roadmaps and implementing pricing and go-to-market strategies for next-generation analytics solutions.